Skip to main content

Table 3 Comparison of patients’ outcome between studied groups

From: A new method for treating fecal incontinence by implanting stem cells derived from human adipose tissue: preliminary findings of a randomized double-blind clinical trial

Variable

Total

Control group

hADSC-treated group

p

Wexner score (mean ± SD)

 Baseline

8.17 ± 3.74

6.0 ± 1.18

10.33 ± 0.87

0.02*

 Post intervention

4.56 ± 3.22

2.67 ± 0.62

6.44 ± 1.08

0.36#

Standardized mean difference (95% confidence interval)a

3.73 (2.61–4.86)

3.63 (2.0–5.07)

3.97 (2.31–5.62)

0.41

Percentage of muscle occupied area (mean ± SD)

15.25 ± 7.34

11.65 ± 7.74

18.85 ± 5.06

0.02*

Electromyography recording (n, %)

 Negative

10 (58.82)

9 (100.0)

1 (12.50)

0.002*

 Positive

7 (41.18)

0 (0.0)

7 (87.50)

 
  1. Control group sphincteroplasty alone, hADSC-treated group human adipose-derived stem cells + sphincteroplasty, SD standard deviation
  2. aBased on Hedge’s g
  3. *Based on Mann–Whitney U test
  4. #Based on nonparametric ANCOVA test